COCP Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (19 Apr 2024 @ 16:00):

Cocrystal Pharma, Inc., a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases...

Stats
Today's Volume	9 576.00
Average Volume	14 228.00
Market Cap	15.56M
EPS	$0 ( 2024-04-03 )
Next earnings date	( $-0.560 ) 2024-05-20
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.820
ATR14	$0.0250 (1.63%)

Insider Trading

Date	Person	Action	Amount	type
2023-07-18	Frost Phillip Md Et Al	Buy	19 333	Stock Options (Right to Buy)
2023-07-18	Japour Anthony J	Buy	13 567	Stock Options (Right to Buy)
2023-07-18	Martin James Joseph	Buy	30 000	Stock Options (Right to Buy)
2023-07-18	Kornberg Roger D.	Buy	24 417	Stock Options (Right to Buy)
2023-07-18	Lee Sam	Buy	30 000	Stock Options (Right to Buy)

INSIDER POWER
100.00
Last 92 transactions
Buy: 58 610 813 \| Sell: 4 956 864

Cocrystal Pharma Inc Correlation

10 Most Positive Correlations
EGRX	0.876
SQQQ	0.873
FHTX	0.846
FEAM	0.845
AOSL	0.831
DLPN	0.825
ATEX	0.822
DRTS	0.812
ALLT	0.809
EMXC	0.807

10 Most Negative Correlations
NYMTL	-0.892
NYMTM	-0.878
HLNE	-0.877
LFUS	-0.87
MAR	-0.87
NYMTN	-0.864
PTF	-0.863
OSIS	-0.856
SMH	-0.855
JSML	-0.854

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Cocrystal Pharma Inc Financials

Annual	2023
Revenue:	$0
Gross Profit:	$1.39M (0.00 %)
EPS:	$-1.860

Q4	2023
Revenue:	$0
Gross Profit:	$0 (0.00 %)
EPS:	$-0.440

Q3	2023
Revenue:	$0
Gross Profit:	$-108 000 (0.00 %)
EPS:	$-0.410

Q2	2023
Revenue:	$0
Gross Profit:	$-101 000 (0.00 %)
EPS:	$-0.410

Financial Reports:

No articles found.

Cocrystal Pharma Inc

Cocrystal Pharma, Inc., a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases. It employs structure-based technologies to create antiviral drugs primarily to treat hepatitis C virus (HCV), influenza virus, coronavirus, and norovirus infections. The company develops CC-31244, a HCV non-nucleoside polymerase inhibitor that has completed Phase II a clinical trial to treat HCV infection; and CC-42344, a PB2 inhibitor that is in preclinical development trials for treating influenza infection. It is also involved in identifying and developing non-nucleoside polymerase inhibitors for norovirus infections. Cocrystal Pharma, Inc. has a license and research collaboration agreement with Merck Sharp & Dohme Corp. to discover and develop proprietary influenza A/B antiviral agents; a license agreement with Kansas State University Research Foundation to develop antiviral compounds for the treatment of norovirus and coronavirus infections; and drug discovery collaboration with HitGen and InterX Inc. The company is headquartered in Bothell, Washington.